Core–shell magnetic nanoparticles display synergistic antibacterial effects against Pseudomonas aeruginosa and Staphylococcus aureus when combined with cathelicidin LL-37 or selected ceragenins

Core–shell magnetic nanoparticles (MNPs) are promising candidates in the development of new treatment methods against infections, including those caused by antibiotic-resistant pathogens. In this study, the bactericidal activity of human antibacterial peptide cathelicidin LL-37, synthetic ceragenins CSA-13 and CSA-131, and classical antibiotics vancomycin and colistin, against methicillin-resistant Staphylococcus aureus Xen 30 and Pseudomonas aeruginosa Xen 5, was assessed alone and in combination with core–shell MNPs. Fractional inhibitory concentration index and fractional bactericidal concentration index were determined by microdilution methods. The potential of combined therapy using nanomaterials and selected antibiotics was confirmed using chemiluminescence measurements. Additionally, the ability of tested agents to prevent bacterial biofilm formation was evaluated using crystal violet staining. In most conditions, synergistic or additive effects were observed when combinations of core–shell MNPs with ceragenins or classical antibiotics were used. Our study revealed that a mixture of membrane-active agents such as LL-37 peptide or ceragenin CSA-13 with MNPs potentialized their antibacterial properties and might be considered as a method of delaying and overcoming bacterial drug resistance.

[1]  J. Suaya,et al.  Incidence, microbiology, and patient characteristics of skin and soft-tissue infections in a U.S. population: a retrospective population-based study , 2013, BMC Infectious Diseases.

[2]  V. Adam,et al.  Magnetic nanoparticles and targeted drug delivering. , 2010, Pharmacological research.

[3]  Young Jik Kwon,et al.  "Nanoantibiotics": a new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[4]  R. Massart,et al.  Preparation of aqueous magnetic liquids in alkaline and acidic media , 1981 .

[5]  T. White,et al.  Synthesis of gold nanoshells based on the depositionprecipitation process , 2008 .

[6]  J. Forrest,et al.  Squalamine: an aminosterol antibiotic from the shark. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Kevin Francis,et al.  Direct Continuous Method for Monitoring Biofilm Infection in a Mouse Model , 2003, Infection and Immunity.

[8]  P. Janmey,et al.  Potential of ceragenin CSA‐13 and its mixture with pluronic F‐127 as treatment of topical bacterial infections , 2011, Journal of applied microbiology.

[9]  R. Watkins,et al.  Current concepts on the virulence mechanisms of meticillin-resistant Staphylococcus aureus. , 2012, Journal of medical microbiology.

[10]  Stefan Schwarz,et al.  A Field Guide to Pandemic, Epidemic and Sporadic Clones of Methicillin-Resistant Staphylococcus aureus , 2011, PloS one.

[11]  G. Mogoșanu,et al.  Biocompatible Fe3O4 Increases the Efficacy of Amoxicillin Delivery against Gram-Positive and Gram-Negative Bacteria , 2014, Molecules.

[12]  R. Pathania,et al.  Synergistic action of cinnamaldehyde with silver nanoparticles against spore-forming bacteria: a case for judicious use of silver nanoparticles for antibacterial applications , 2013, International journal of nanomedicine.

[13]  P. Savage,et al.  Potential Synergy Activity of the Novel Ceragenin, CSA-13, against Carbapenem-Resistant Acinetobacter baumannii Strains Isolated from Bacteremia Patients , 2014, BioMed research international.

[14]  H. Car,et al.  Nanoparticles as drug delivery systems , 2012, Pharmacological reports : PR.

[15]  T. Webster,et al.  Synthesis, characterization, controlled release, and antibacterial studies of a novel streptomycin chitosan magnetic nanoantibiotic , 2014, International journal of nanomedicine.

[16]  A. Wilczewska,et al.  Surface‐Initiated RAFT/MADIX Polymerization on Xanthate‐Coated Iron Oxide Nanoparticles , 2014 .

[17]  Herman Goossens,et al.  A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance , 2014, BMC Infectious Diseases.

[18]  S. Kannan,et al.  Update on bacterial nosocomial infections. , 2012, European review for medical and pharmacological sciences.

[19]  P. Maurya,et al.  Non-Cytotoxic Nanomaterials Enhance Antimicrobial Activities of Cefmetazole against Multidrug-Resistant Neisseria gonorrhoeae , 2013, PloS one.

[20]  Julie Morris,et al.  Clinical outcome for cystic fibrosis patients infected with transmissible pseudomonas aeruginosa: an 8-year prospective study. , 2010, Chest.

[21]  Sherine O. Obare,et al.  Nanoparticles Functionalized with Ampicillin Destroy Multiple-Antibiotic-Resistant Isolates of Pseudomonas aeruginosa and Enterobacter aerogenes and Methicillin-Resistant Staphylococcus aureus , 2012, Applied and Environmental Microbiology.

[22]  Erik N. Taylor,et al.  Short communication: carboxylate functionalized superparamagnetic iron oxide nanoparticles (SPION) for the reduction of S. aureus growth post biofilm formation , 2013, International journal of nanomedicine.

[23]  Kai Hilpert,et al.  Synergistic Interaction between Silver Nanoparticles and Membrane-Permeabilizing Antimicrobial Peptides , 2009, Antimicrobial Agents and Chemotherapy.

[24]  A. Ingle,et al.  Silver nanoparticles: the powerful nanoweapon against multidrug‐resistant bacteria , 2012, Journal of applied microbiology.

[25]  P. Janmey,et al.  Resistance of the antibacterial agent ceragenin CSA-13 to inactivation by DNA or F-actin and its activity in cystic fibrosis sputum. , 2007, The Journal of antimicrobial chemotherapy.

[26]  P. Savage,et al.  Antibacterial properties of cationic steroid antibiotics. , 2002, FEMS microbiology letters.

[27]  Morteza Mahmoudi,et al.  Magnetic fluid hyperthermia: focus on superparamagnetic iron oxide nanoparticles. , 2011, Advances in colloid and interface science.

[28]  P. Boura,et al.  The immune system, natural autoantibodies and general homeostasis in health and disease. , 2011, Hippokratia.

[29]  Bing Xu,et al.  Presenting Vancomycin on Nanoparticles to Enhance Antimicrobial Activities , 2003 .

[30]  O. Corrigan,et al.  Pharmacokinetics of amphotericin B lipid complex in critically ill patients undergoing continuous venovenous haemodiafiltration. , 2013, International journal of antimicrobial agents.

[31]  E. Isogai,et al.  Ceragenin CSA-13 induces cell cycle arrest and antiproliferative effects in wild-type and p53 null mutant HCT116 colon cancer cells , 2013, Anti-cancer drugs.

[32]  P. Janmey,et al.  Antibacterial activity of the human host defence peptide LL-37 and selected synthetic cationic lipids against bacteria associated with oral and upper respiratory tract infections. , 2013, The Journal of antimicrobial chemotherapy.

[33]  H. Verbrugh,et al.  Nasal carriage of Staphylococcus aureus as a major risk factor for wound infections after cardiac surgery. , 1995, The Journal of infectious diseases.

[34]  P. Janmey,et al.  Polyelectrolyte-mediated increase of biofilm mass formation , 2015, BMC Microbiology.

[35]  A. van Belkum,et al.  Co-evolutionary aspects of human colonisation and infection by Staphylococcus aureus. , 2009, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[36]  F. Can,et al.  In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. , 2006, International journal of antimicrobial agents.

[37]  P. Savage,et al.  In vitro Activities of the Novel Ceragenin CSA-13, Alone or in Combination with Colistin, Tobramycin, and Ciprofloxacin, against Pseudomonas aeruginosa Strains Isolated from Cystic Fibrosis Patients , 2012, Chemotherapy.

[38]  P. Savage,et al.  Ceragenin CSA-13 exhibits antimicrobial activity against cariogenic and periodontopathic bacteria. , 2009, Oral microbiology and immunology.

[39]  M. Welsh,et al.  Synergistic and additive killing by antimicrobial factors found in human airway surface liquid. , 2000, American journal of physiology. Lung cellular and molecular physiology.

[40]  Biju Jacob,et al.  Toxicity and antibacterial assessment of chitosancoated silver nanoparticles on human pathogens and macrophage cells , 2012, International journal of nanomedicine.

[41]  R. Epand,et al.  Ceragenins: cholic acid-based mimics of antimicrobial peptides. , 2008, Accounts of chemical research.

[42]  S. Gurunathan,et al.  Enhanced antibacterial and anti-biofilm activities of silver nanoparticles against Gram-negative and Gram-positive bacteria , 2014, Nanoscale Research Letters.

[43]  R. Bang,et al.  Pseudomonas aeruginosa septicaemia in burns. , 1999, Burns : journal of the International Society for Burn Injuries.

[44]  H. Nagabhushana,et al.  Combustion synthesis, characterization and Raman studies of ZnO nanopowders. , 2011, Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.

[45]  P. Janmey,et al.  Antibacterial Activities of Rhodamine B-Conjugated Gelsolin-Derived Peptides Compared to Those of the Antimicrobial Peptides Cathelicidin LL37, Magainin II, and Melittin , 2004, Antimicrobial Agents and Chemotherapy.

[46]  R. Bucki,et al.  Extracellular DNA as an essential component and therapeutic target of microbial biofilm , 2015 .

[47]  S. Chatterjee,et al.  Biofilms on Indwelling Urologic Devices: Microbes and Antimicrobial Management Prospect , 2014, Annals of medical and health sciences research.

[48]  Y. Onlen,et al.  Evaluation of nosocomial infections and risk factors in critically ill patients , 2011, Medical science monitor : international medical journal of experimental and clinical research.

[49]  G. Mogoșanu,et al.  Iron oxide nanoparticles modulate the interaction of different antibiotics with cellular membranes. , 2014, Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie.

[50]  H. Car,et al.  Magnetic nanoparticles as new diagnostic tools in medicine. , 2012, Advances in medical sciences.

[51]  P. Stewart,et al.  Study of the effect of antimicrobial peptide mimic, CSA-13, on an established biofilm formed by Pseudomonas aeruginosa , 2013, MicrobiologyOpen.

[52]  Ronald N. Jones,et al.  Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of Pseudomonas aeruginosa, including multidrug-resistant P. aeruginosa. , 2007, The Journal of antimicrobial chemotherapy.

[53]  I. Olsen,et al.  Biofilm-specific antibiotic tolerance and resistance , 2015, European Journal of Clinical Microbiology & Infectious Diseases.

[54]  I. Swiecicka,et al.  Growth arrest and rapid capture of select pathogens following magnetic nanoparticle treatment. , 2015, Colloids and surfaces. B, Biointerfaces.

[55]  M. Zasloff,et al.  Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[56]  K. Lewis,et al.  Pseudomonas aeruginosa Biofilms in Disease , 2013, Microbial Ecology.

[57]  Naeem Ali,et al.  Combined efficacy of biologically synthesized silver nanoparticles and different antibiotics against multidrug-resistant bacteria , 2013, International journal of nanomedicine.

[58]  Ruchi Yadav,et al.  Biogenic synthesis of silver nanoparticles and their synergistic effect with antibiotics: a study against gram-positive and gram-negative bacteria. , 2010, Nanomedicine : nanotechnology, biology, and medicine.

[59]  P. Savage,et al.  Antimicrobial Activities of Ceragenins against Clinical Isolates of Resistant Staphylococcus aureus , 2007, Antimicrobial Agents and Chemotherapy.

[60]  I. Swiecicka,et al.  Gold-functionalized magnetic nanoparticles restrict growth of Pseudomonas aeruginosa , 2014, International journal of nanomedicine.

[61]  K. Leszczynska,et al.  Cathelicidin LL-37: A Multitask Antimicrobial Peptide , 2010, Archivum Immunologiae et Therapiae Experimentalis.